Antares Pharma, Inc. (ATRS)

[Birdstone]

If that's the case they might as well re-price the stock at $2 so we can start moving higher. The market is supposed to discount future revenues and earnings. It just seems that's not the case with ATRS. The stock has been down in almost a straight line since Feb. 20th. 33%. A third of its value. In a little over a month. With revenues beginning to accelerate.

Talk about brutal.